** Shares of Senti Biosciences SNTI.O more than double to $5.23; last up 139.5%
** Co says its cell therapy for cancer that has either come back or stop responding to treatment caused a complete remission in 2 of 3 patients in an early-stage trial
** Complete remission is the disappearance of all signs of cancer in response to treatment
** SNTI says additional safety and efficacy data, including initial durability data on the therapy SENTI-202, are expected to follow in 2025
** Co says it has also entered into a securities purchase agreement with some investors to issue and sell about 16,713 Series A preferred stock through a private investment in public equity or PIPE financing
** SNTI expects gross proceeds from financing to be about $37.6 mln, plans to use them along with existing cash towards SENTI-202 development and manufacturing, other R&D activities, and for general corporate purposes
** Up to last close, stock down 67.3% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."